Astellas Invests in Future of Frontotemporal Dementia Treatment with AviadoBio Partnership

Astellas Invests in Future of Frontotemporal Dementia Treatment with AviadoBio Partnership

by John Conrad| Oct 8, 2024| Member News

Astellas Pharma Inc. and AviadoBio Ltd. have announced an exclusive option and license agreement for AVB-101, a promising gene therapy currently in Phase 1/2 clinical trials. This collaboration marks a significant step forward in addressing the urgent need for effective treatments for FTD, particularly for patients with progranulin mutations (FTD-GRN).

FTD is a devastating form of early-onset dementia that typically leads to death within 3 to 13 years of diagnosis. It primarily affects individuals under 65, causing rapid decline in executive function, uncharacteristic behaviors, language loss, and reduced mobility. The disease is often underrecognized and misdiagnosed, making advancements in treatment all the more critical.

Under the terms of the agreement, Astellas will receive an exclusive option for worldwide rights to develop and commercialize AVB-101 for FTD-GRN and potentially other indications. The deal includes a $20 million equity investment in AviadoBio and up to $30 million in upfront payments. If Astellas exercises its option, AviadoBio could receive up to $2.18 billion in additional fees and milestone payments, plus royalties.

Lisa Deschamps, CEO of AviadoBio, expressed excitement about the collaboration's potential to address the unmet needs in FTD treatment. She highlighted the synergy between AviadoBio's gene therapy expertise and Astellas' global capabilities in development and commercialization.

Adam Pearson, Chief Strategy Officer at Astellas, emphasized the innovative approach of AVB-101 and its potential to be part of the next generation of gene therapy products. He reiterated Astellas' commitment to genetic regulation as a cornerstone of their primary focus strategy.

This partnership represents a convergence of cutting-edge science and global resources, potentially accelerating the development of life-changing treatments for patients with FTD-GRN and other neurological diseases. As the clinical trials progress, the medical community and patients alike will be watching closely for results that could transform the landscape of FTD treatment.

[This article was created from a press release issued by Astellas and AviadoBio on October 8, 2024.]